Posted inBiotechnology
Family Dynamics and Behavioral Challenges in Autistic Kids
In recent years, the exploration of autism spectrum disorder (ASD) has gained significant focus in research, shedding light on the…
Posted inBiotechnology
Curcumin’s Role in Prostate Cancer Therapy
In the relentless battle against prostate cancer, a beacon of hope emerges from the ancient spice turmeric. A newly published…
Posted inBiotechnology
Exploring DSM-5 Traits in Eating Disorder Treatment
Recent research has shed light on the intricate relationship between personality traits and eating disorders, revealing critical insights that could…
Posted inBiotechnology
Optimizing Care for Saudi CKD Patients with Comorbidities
The prevalence of chronic kidney disease (CKD) has reached alarming levels worldwide, and this condition is particularly problematic in Saudi…
Posted inBiotechnology
Medwakh Smoking Alters Salivary Proteins and Cytokines
In a groundbreaking study, researchers have unveiled the profound impact of Medwakh smoking on salivary proteins and cytokine expression. This…
Posted inBiotechnology
ESMO 2025: Belzutifan Demonstrates Tumor Reduction and Symptom Relief in Patients with Rare Neuroendocrine Tumors
In a landmark advancement for the treatment of rare neuroendocrine tumors, researchers have reported groundbreaking results with the oral HIF-2α…
Posted inBiotechnology
Study: Shugan Jieyu Capsules Boost Zolpidem for Insomnia
In the quest to find effective treatments for insomnia, particularly when accompanied by depressive symptoms, recent research has shed light…
Posted inBiotechnology
New Treatment Combination Enhances Progression-Free Survival in Metastatic ER-Positive, HER2-Negative Breast Cancer
In a landmark advancement for the treatment of metastatic estrogen-receptor-positive (ER-positive), HER-2-negative breast cancer, new clinical trial results reveal a…
Posted inBiotechnology
ESMO: Tubulis’ next-gen ADC posts 59% response rate, justifying investor interest
Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German biotech…
Posted inBiotechnology
ESMO: GSK says ‘stay tuned’ for more ADC data after partner Hansoh posts 49% response rate
GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates (ADCs), but the Big Pharma’s oncology R&D…